Oramed Pharmaceuticals (ORMP) Competitors $2.15 -0.05 (-2.27%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$2.15 +0.00 (+0.23%) As of 04/17/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ORMP vs. ETON, VERV, ORIC, TRML, KMDA, RAPP, ALT, AUTL, ERAS, and SNDLShould you be buying Oramed Pharmaceuticals stock or one of its competitors? The main competitors of Oramed Pharmaceuticals include Eton Pharmaceuticals (ETON), Verve Therapeutics (VERV), ORIC Pharmaceuticals (ORIC), Tourmaline Bio (TRML), Kamada (KMDA), Rapport Therapeutics (RAPP), Altimmune (ALT), Autolus Therapeutics (AUTL), Erasca (ERAS), and SNDL (SNDL). These companies are all part of the "pharmaceutical products" industry. Oramed Pharmaceuticals vs. Eton Pharmaceuticals Verve Therapeutics ORIC Pharmaceuticals Tourmaline Bio Kamada Rapport Therapeutics Altimmune Autolus Therapeutics Erasca SNDL Eton Pharmaceuticals (NASDAQ:ETON) and Oramed Pharmaceuticals (NASDAQ:ORMP) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, dividends, risk, community ranking and institutional ownership. Does the MarketBeat Community favor ETON or ORMP? Oramed Pharmaceuticals received 221 more outperform votes than Eton Pharmaceuticals when rated by MarketBeat users. Likewise, 72.50% of users gave Oramed Pharmaceuticals an outperform vote while only 65.77% of users gave Eton Pharmaceuticals an outperform vote. CompanyUnderperformOutperformEton PharmaceuticalsOutperform Votes9865.77% Underperform Votes5134.23% Oramed PharmaceuticalsOutperform Votes31972.50% Underperform Votes12127.50% Is ETON or ORMP more profitable? Oramed Pharmaceuticals has a net margin of 0.00% compared to Eton Pharmaceuticals' net margin of -15.81%. Oramed Pharmaceuticals' return on equity of -7.27% beat Eton Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Eton Pharmaceuticals-15.81% -36.29% -16.84% Oramed Pharmaceuticals N/A -7.27%-6.20% Which has more volatility and risk, ETON or ORMP? Eton Pharmaceuticals has a beta of 1.34, suggesting that its share price is 34% more volatile than the S&P 500. Comparatively, Oramed Pharmaceuticals has a beta of 1.5, suggesting that its share price is 50% more volatile than the S&P 500. Does the media favor ETON or ORMP? In the previous week, Eton Pharmaceuticals had 1 more articles in the media than Oramed Pharmaceuticals. MarketBeat recorded 3 mentions for Eton Pharmaceuticals and 2 mentions for Oramed Pharmaceuticals. Eton Pharmaceuticals' average media sentiment score of 0.51 beat Oramed Pharmaceuticals' score of 0.34 indicating that Eton Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eton Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oramed Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals and insiders have more ownership in ETON or ORMP? 27.9% of Eton Pharmaceuticals shares are owned by institutional investors. Comparatively, 12.7% of Oramed Pharmaceuticals shares are owned by institutional investors. 14.9% of Eton Pharmaceuticals shares are owned by company insiders. Comparatively, 13.7% of Oramed Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has better earnings and valuation, ETON or ORMP? Oramed Pharmaceuticals has lower revenue, but higher earnings than Eton Pharmaceuticals. Eton Pharmaceuticals is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEton Pharmaceuticals$39.01M9.86-$940K-$0.15-95.60Oramed Pharmaceuticals$1.34M65.54$5.53M-$0.21-10.24 Do analysts recommend ETON or ORMP? Eton Pharmaceuticals currently has a consensus price target of $27.67, indicating a potential upside of 92.93%. Given Eton Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Eton Pharmaceuticals is more favorable than Oramed Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eton Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Oramed Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 SummaryEton Pharmaceuticals and Oramed Pharmaceuticals tied by winning 9 of the 18 factors compared between the two stocks. Get Oramed Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ORMP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ORMP vs. The Competition Export to ExcelMetricOramed PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$87.83M$6.46B$5.31B$7.35BDividend YieldN/A3.20%5.45%4.31%P/E Ratio19.556.9521.9417.82Price / Sales65.54231.01380.9497.68Price / CashN/A65.6738.2634.64Price / Book0.535.936.453.98Net Income$5.53M$143.22M$3.22B$247.81M7 Day Performance1.90%4.28%5.85%3.19%1 Month Performance-9.28%-13.11%-9.55%-7.70%1 Year Performance-5.29%-8.51%11.83%1.49% Oramed Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ORMPOramed Pharmaceuticals1.46 of 5 stars$2.15-2.3%N/A-5.3%$87.83M$1.34M19.5510Positive NewsGap UpETONEton Pharmaceuticals2.2908 of 5 stars$13.72+10.2%$27.67+101.7%+349.5%$367.94M$39.01M-62.3620Short Interest ↑VERVVerve Therapeutics3.0741 of 5 stars$4.12+26.4%$24.00+482.5%-30.9%$365.84M$32.33M-1.67110Analyst ForecastOptions VolumeNews CoverageHigh Trading VolumeORICORIC Pharmaceuticals3.2606 of 5 stars$5.11+3.9%$18.86+269.0%-48.1%$362.95MN/A-2.8180Positive NewsGap UpTRMLTourmaline Bio2.722 of 5 stars$14.09+7.6%$45.20+220.8%+3.6%$361.90MN/A-5.0044News CoveragePositive NewsKMDAKamada3.8637 of 5 stars$6.28+3.5%$14.67+133.5%+28.7%$360.97M$160.95M22.43360Short Interest ↓Gap UpRAPPRapport Therapeutics1.6633 of 5 stars$9.84+6.3%$32.67+232.0%N/A$359.12MN/A-0.71N/AShort Interest ↑ALTAltimmune2.7968 of 5 stars$4.63+5.0%$20.83+350.0%-34.1%$356.58M$20,000.00-2.9950Positive NewsAUTLAutolus Therapeutics2.1306 of 5 stars$1.34-1.5%$9.32+595.5%-68.4%$356.57M$10.12M-1.11330Positive NewsGap UpERASErasca3.3615 of 5 stars$1.24flat$4.83+289.8%-35.2%$351.25MN/A-1.49120Short Interest ↓SNDLSNDL3.0126 of 5 stars$1.33-2.2%$3.63+172.6%-25.1%$349.49M$920.45M-4.29580Positive News Related Companies and Tools Related Companies Eton Pharmaceuticals Competitors Verve Therapeutics Competitors ORIC Pharmaceuticals Competitors Tourmaline Bio Competitors Kamada Competitors Rapport Therapeutics Competitors Altimmune Competitors Autolus Therapeutics Competitors Erasca Competitors SNDL Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ORMP) was last updated on 4/20/2025 by MarketBeat.com Staff From Our PartnersMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredThe real reason gold is soaring (and likely to continue)Trump’s Policies Are Fueling a Gold Boom—Here’s Your Chance to Profit Donald Trump’s bold policies are driv...Golden Portfolio | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oramed Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oramed Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ORMP Stock Free ORMP Stock Alerts